Collaborations - Additional Information (Detail) $ in Thousands	1 Months Ended			12 Months Ended
	Oct. 31, 2023 program	Oct. 31, 2022 USD ($)	Jul. 31, 2018	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				$ 219,638	$ 299,489	$ 271,893
Cost of revenue				120,261	164,993	138,948
Accounts payable				42,263	66,430
Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				12,004	47,448	46,064
Cost of revenue				295	530	299
GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement, period			4 years
Aggregate cash consideration for collaboration arrangement		$ 50,000
GSK | Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue for customer services					11,800
Revenue				11,800	47,400	46,100
Cost of revenue				300	500	300
Research and development expense				12,800	10,700	24,000
Accounts payable				10,600	11,900
GSK 2023 Amendment
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from license fees				20,000
License for data access expiration period	1 year
Programs, opted-out of cost sharing and other research and development | program	3
GSK 2023 Amendment | Related Party
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue for customer services				20,000
Revenue				$ 0	$ 0	$ 0